In a new study published in The BMJ, researchers found that using two new classes of T2D drugs together yielded benefits. When study participants took GLP-1 receptor agonists therapy added to a SGLT-2 inhibitor, they curtailed their risk of major adverse cardiovascular events by about 30% compared with taking an agent from just one class. The likelihood for serious renal events was also lower with combination therapy.